BlinkLab
@blink_lab
Followers
118
Following
109
Media
65
Statuses
131
Digital Sensory Phenotyping for Autism and ADHD
Princeton
Joined November 2021
BlinkLab Limited (ASX:BB1), a leading digital healthcare company focused on AI-powered diagnostics, is pleased to announce it has engaged The University of Pennsylvania Perelman School of Medicine as its third clinical site for its ongoing FDA 510(k) diagnostic trial for the
0
1
3
BlinkLab Non-Executive Chairman, Brian Leedman, is pleased to be presenting at the TechKnow Invest Roadshow. Register via . Please email info@janemorganmanagement.com.au to arrange a 1:1 meeting. $BB1 #awareness #autismspeaks @VEvents_RIU
0
1
1
BlinkLab Non-Executive Chairman, Brian Leedman, is pleased to be presenting at the TechKnow Invest Roadshow. Download the latest Investor presentation: Please email info@janemorganmanagement.com.au to arrange a 1:1 meeting. $BB1.ax #awareness
0
1
3
🔊 REMINDER: Brian Leedman presenting TODAY!.
BlinkLab Non-Executive Chairman, Brian Leedman, is pleased to be presenting at the TechKnow Invest Roadshow. Register via Please email info@janemorganmanagement.com.au to arrange a 1:1 meeting. $BB1 #awareness #autismspeaks @VEvents_RIU
0
1
1
Blinklab is pleased to be included in the recent @StockheadAU article "Morgans spotlights nine healthcare stocks with upcoming catalysts". Read more: $BB1 #awareness #autismspeaks.
0
1
1
BlinkLab Non-Executive Chairman, Brian Leedman, is pleased to be presenting at the TechKnow Invest Roadshow. Register via Please email info@janemorganmanagement.com.au to arrange a 1:1 meeting. $BB1 #awareness #autismspeaks @VEvents_RIU
0
1
1
🔊 REMINDER: BlinkLab Limited (ASX:BB1) Non-Executive Chairman, Brian Leedman, presenting TODAY!.
BlinkLab Limited (ASX:BB1) Non-Executive Chairman, Brian Leedman, is pleased to be presenting at the 19th Bioshares Biotech Summit. Register via Please email info@janemorganmanagement.com.au to arrange a 1:1 meeting. $BB1 #awareness #autismspeaks
0
0
0
BlinkLab Limited (ASX:BB1) Non-Executive Chairman, Brian Leedman, is pleased to be presenting at the 19th Bioshares Biotech Summit. Register via Please email info@janemorganmanagement.com.au to arrange a 1:1 meeting. $BB1 #awareness #autismspeaks
0
1
5
BlinkLab (ASX:BB1) is pleased to provide shareholders and investors with its activities report to accompany the Appendix 5B for the quarter ending 30 June 2025. Read more: $BB1 #awareness #autismspeaks
0
1
1
BlinkLab Limited (ASX:BB1) is pleased to announce the engagement of the University of Nebraska Medical Center (UNMC) as a key clinical partner in the main study phase of its pivotal U.S. FDA 510(k) diagnostic trial for BlinkLab Dx 1, a smartphone-based digital tool designed to
0
1
1
Dr Henk-Jan Boele from BlinkLab Limited (ASX:BB1) shares insights on the company's AI-driven diagnostic platform. This technology uses facial reflex responses, captured via smartphone, to assess neurodevelopmental conditions such as autism and ADHD in children as young as 18
0
1
1
BlinkLab Limited (ASX:BB1), a leading digital healthcare company specializing in AI-powered diagnostics, is pleased to announce that it has received Institutional Review Board (IRB) approval for the main study phase of its FDA 510(k) diagnostic trial evaluating the BlinkLab Dx 1
0
5
9
From the teams at @blink_lab, @ECR_Australia, and @JMM_Australia, our heartfelt thanks again to everyone who attended the BlinkLab Investor Lunch in Sydney last week. BlinkLab’s Chairman, Mr Brian Leedman, gave a presentation to a range of existing shareholders and investors
0
1
2
A heartfelt thank you to everyone who attended today’s successful investor lunch in Sydney, hosted by Company Chairman, Brian Leedman, and Non-Executive Director, Jane Morgan. We were pleased to share BlinkLab’s progress with both long-term shareholders and new potential
0
1
4
BlinkLab engages leading autism research centre for main study phase of US diagnostic trial. Read more: $BB1.ax #awareness #autismspeaks.
biotechdispatch.com.au
BlinkLab (ASX:BB1) has announced the commencement of the main study phase of its pivotal US-based FDA 510(k) diagnostic trial for its smartphone-based autism diagnostic tool, with the engagement of a...
0
1
3
BlinkLab Limited (ASX:BB1), a leading digital healthcare company focused on AI-powered diagnostics, is pleased to announce that it has engaged The Southwest Autism Research & Resource Center as a new clinical site for the main study phase of BlinkLab Dx 1’s ongoing FDA 510(k)
0
1
1
WA diagnostics startup BlinkLab has raised nearly $8 million to bankroll a clinical trial for its smartphone autism test ahead of a US Food and Drug Administration submission. BlinkLab emerged from a trading halt on Thursday to announce it had completed a placement to domestic
1
1
3
BlinkLab Limited (ASX:BB1), a leading digital healthcare company focused on AI-powered diagnostics, is pleased to announce that it has successfully completed a wellsupported placement to sophisticated and institutional investors; raising a total of A$7.66M (before costs) at a
0
1
2
BlinkLab Limited (ASX:BB1), a leading digital healthcare company focused on AI-powered diagnostics, is pleased to present an overview of the Company’s activities for the reporting period ended 31 March 2025. Read more: $BB1.ax #awareness #autismspeaks
0
0
1